

Beta-lactam and Beta-lactamase Inhibitors Industry Research Report 2023

<https://marketpublishers.com/r/B949DC657C60EN.html>

Date: August 2023

Pages: 104

Price: US\$ 2,950.00 (Single User License)

ID: B949DC657C60EN

Abstracts

Highlights

The global Beta-lactam and Beta-lactamase Inhibitors market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

North American market for Beta-lactam and Beta-lactamase Inhibitors is estimated to increase from \$ million in 2022 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Beta-lactam and Beta-lactamase Inhibitors is estimated to increase from \$ million in 2022 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The major global manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma and Wockhardt, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

The global market for Beta-lactam and Beta-lactamase Inhibitors in Oral is estimated to increase from \$ million in 2022 to \$ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Penicillins, which accounted for % of the global market of Beta-lactam and Beta-lactamase Inhibitors in 2022, is expected to reach million US\$ by 2029, growing at a

revised CAGR of % from 2023 to 2029.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Beta-lactam and Beta-lactamase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Beta-lactam and Beta-lactamase Inhibitors.

The Beta-lactam and Beta-lactamase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Beta-lactam and Beta-lactamase Inhibitors market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Beta-lactam and Beta-lactamase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2018-2023. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Pfizer

Novartis (Sandoz)

TEVA

Merck

AbbVie (Allergan)

Sumitomo Dainippon

Hikma

Aurobindo Pharma

Wockhardt

Lupin Limited

Fresenius Kabi

B. Braun

USantibiotics

Qilu Pharmaceutical

ACS Dobfar

Nichi-Iko (Sagent)

Antibiotice

Product Type Insights

Global markets are presented by Beta-lactam and Beta-lactamase Inhibitors type, along with growth forecasts through 2029. Estimates on sales and revenue are based on the

price in the supply chain at which the Beta-lactam and Beta-lactamase Inhibitors are procured by the manufacturers.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Beta-lactam and Beta-lactamase Inhibitors segment by Type

Penicillins

Cephalosporins

Carbapenems

Monobactams

Combinations

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Beta-lactam and Beta-lactamase Inhibitors market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Beta-lactam and Beta-lactamase Inhibitors market.

Beta-lactam and Beta-lactamase Inhibitors segment by Application

Oral

Intravenous

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Beta-lactam and Beta-lactamase Inhibitors market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Beta-lactam and Beta-lactamase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Beta-lactam and Beta-lactamase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Beta-lactam and Beta-lactamase Inhibitors industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning

the adoption of Beta-lactam and Beta-lactamase Inhibitors.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Beta-lactam and Beta-lactamase Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Beta-lactam and Beta-lactamase Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Beta-lactam and Beta-lactamase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find

the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size (2018-2029) & (US\$ Million)
 - 2.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales (2018-2029)
 - 2.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Average Price (2018-2029)
- 2.3 Beta-lactam and Beta-lactamase Inhibitors by Type
 - 2.3.1 Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)
 - 1.2.2 Penicillins
 - 1.2.3 Cephalosporins
 - 1.2.4 Carbapenems
 - 1.2.5 Monobactams
 - 1.2.6 Combinations
- 2.4 Beta-lactam and Beta-lactamase Inhibitors by Application
 - 2.4.1 Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)
 - 2.4.2 Oral
 - 2.4.3 Intravenous

3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

- 3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Competitive Situation by Manufacturers (2018 Versus 2022)
- 3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) of Manufacturers

(2018-2023)

3.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue of Manufacturers

(2018-2023)

3.4 Global Beta-lactam and Beta-lactamase Inhibitors Average Price by Manufacturers

(2018-2023)

3.5 Global Beta-lactam and Beta-lactamase Inhibitors Industry Ranking, 2021 VS 2022 VS 2023

3.6 Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Manufacturing Sites & Headquarters

3.7 Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Product Type & Application

3.8 Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Date of Enter into This Industry

3.9 Global Beta-lactam and Beta-lactamase Inhibitors Market CR5 and HHI

3.10 Global Manufacturers Mergers & Acquisition

4 MANUFACTURERS PROFILED

4.1 Pfizer

4.1.1 Pfizer Company Information

4.1.2 Pfizer Business Overview

4.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.1.5 Pfizer Recent Developments

4.2 Novartis (Sandoz)

4.2.1 Novartis (Sandoz) Company Information

4.2.2 Novartis (Sandoz) Business Overview

4.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.2.5 Novartis (Sandoz) Recent Developments

4.3 TEVA

4.3.1 TEVA Company Information

4.3.2 TEVA Business Overview

4.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.3.5 TEVA Recent Developments

4.4 Merck

4.4.1 Merck Company Information

4.4.2 Merck Business Overview

4.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.4.5 Merck Recent Developments

4.5 AbbVie (Allergan)

4.5.1 AbbVie (Allergan) Company Information

4.5.2 AbbVie (Allergan) Business Overview

4.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.5.5 AbbVie (Allergan) Recent Developments

4.6 Sumitomo Dainippon

4.6.1 Sumitomo Dainippon Company Information

4.6.2 Sumitomo Dainippon Business Overview

4.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.6.5 Sumitomo Dainippon Recent Developments

4.7 Hikma

4.7.1 Hikma Company Information

4.7.2 Hikma Business Overview

4.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.7.5 Hikma Recent Developments

6.8 Aurobindo Pharma

4.8.1 Aurobindo Pharma Company Information

4.8.2 Aurobindo Pharma Business Overview

4.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.8.5 Aurobindo Pharma Recent Developments

4.9 Wockhardt

4.9.1 Wockhardt Company Information

4.9.2 Wockhardt Business Overview

4.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.9.5 Wockhardt Recent Developments

4.10 Lupin Limited

4.10.1 Lupin Limited Company Information

4.10.2 Lupin Limited Business Overview

4.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

4.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

4.10.5 Lupin Limited Recent Developments

6.11 Fresenius Kabi

6.11.1 Fresenius Kabi Company Information

6.11.2 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.11.5 Fresenius Kabi Recent Developments

6.12 B. Braun

6.12.1 B. Braun Company Information

6.12.2 B. Braun Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.12.5 B. Braun Recent Developments

6.13 USantibiotics

6.13.1 USantibiotics Company Information

6.13.2 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.13.5 USantibiotics Recent Developments

6.14 Qilu Pharmaceutical

6.14.1 Qilu Pharmaceutical Company Information

6.14.2 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product

Portfolio

6.14.5 Qilu Pharmaceutical Recent Developments

6.15 ACS Dobfar

6.15.1 ACS Dobfar Company Information

6.15.2 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.15.5 ACS Dobfar Recent Developments

6.16 Nichi-Iko (Sagent)

6.16.1 Nichi-Iko (Sagent) Company Information

6.16.2 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.16.5 Nichi-Iko (Sagent) Recent Developments

6.17 Antibiotice

6.17.1 Antibiotice Company Information

6.17.2 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Business Overview

6.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)

6.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

6.17.5 Antibiotice Recent Developments

5 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET SCENARIO BY REGION

5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region: 2018 VS 2022 VS 2029

5.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region: 2018-2029

5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region: 2018-2023

5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region: 2024-2029

5.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2018-2029

5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2018-2023

5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2024-2029

5.4 North America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures

by Country

5.4.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2018 VS 2022 VS 2029

5.4.2 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2029)

5.4.3 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2029)

5.4.4 United States

5.4.5 Canada

5.5 Europe Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country

5.5.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2018 VS 2022 VS 2029

5.5.2 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2029)

5.5.3 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2029)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Russia

5.6 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country

5.6.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2018 VS 2022 VS 2029

5.6.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2029)

5.6.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2029)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Indonesia

5.6.11 Thailand

5.6.12 Malaysia

5.7 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country

5.7.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2018 VS 2022 VS 2029

5.7.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2029)

5.7.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2029)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.8 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country

5.8.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country: 2018 VS 2022 VS 2029

5.8.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2029)

5.8.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2029)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

6 SEGMENT BY TYPE

6.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029)

6.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)

6.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2018-2029)

6.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2018-2029)

6.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (US\$ Million)

6.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2018-2029)

6.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2018-2029)

7 SEGMENT BY APPLICATION

7.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029)

7.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)

7.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2018-2029)

7.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2018-2029)

6.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (US\$ Million)

6.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2018-2029)

7.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2018-2029)

8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET

8.1 Beta-lactam and Beta-lactamase Inhibitors Value Chain Analysis

8.1.1 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process

8.2 Beta-lactam and Beta-lactamase Inhibitors Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Beta-lactam and Beta-lactamase Inhibitors Distributors

8.2.3 Beta-lactam and Beta-lactamase Inhibitors Customers

9 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS ANALYZING MARKET DYNAMICS

9.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends

9.2 Beta-lactam and Beta-lactamase Inhibitors Industry Drivers

9.3 Beta-lactam and Beta-lactamase Inhibitors Industry Opportunities and Challenges

9.4 Beta-lactam and Beta-lactamase Inhibitors Industry Restraints

10 REPORT CONCLUSION

11 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Beta-lactam and Beta-lactamase Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)

Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Sales (M Units) of Manufacturers (2018-2023)

Table 7. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2018-2023)

Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Revenue of Manufacturers (2018-2023)

Table 9. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers (2018-2023)

Table 10. Global Market Beta-lactam and Beta-lactamase Inhibitors Average Price (US\$/Unit) of Manufacturers (2018-2023)

Table 11. Global Beta-lactam and Beta-lactamase Inhibitors Industry Ranking, 2021 VS 2022 VS 2023

Table 12. Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Product Type & Application

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Beta-lactam and Beta-lactamase Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)

Table 16. Pfizer Company Information

Table 17. Pfizer Business Overview

Table 18. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 19. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

Table 20. Pfizer Recent Developments

Table 21. Novartis (Sandoz) Company Information

Table 22. Novartis (Sandoz) Business Overview

Table 23. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

- Table 24. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 25. Novartis (Sandoz) Recent Developments
- Table 26. TEVA Company Information
- Table 27. TEVA Business Overview
- Table 28. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 29. TEVA Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 30. TEVA Recent Developments
- Table 31. Merck Company Information
- Table 32. Merck Business Overview
- Table 33. Merck Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 34. Merck Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 35. Merck Recent Developments
- Table 36. AbbVie (Allergan) Company Information
- Table 37. AbbVie (Allergan) Business Overview
- Table 38. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 39. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 40. AbbVie (Allergan) Recent Developments
- Table 41. Sumitomo Dainippon Company Information
- Table 42. Sumitomo Dainippon Business Overview
- Table 43. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 44. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 45. Sumitomo Dainippon Recent Developments
- Table 46. Hikma Company Information
- Table 47. Hikma Business Overview
- Table 48. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 49. Hikma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 50. Hikma Recent Developments
- Table 51. Aurobindo Pharma Company Information
- Table 52. Aurobindo Pharma Business Overview
- Table 53. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

- Table 54. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 55. Aurobindo Pharma Recent Developments
- Table 56. Wockhardt Company Information
- Table 57. Wockhardt Business Overview
- Table 58. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 59. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 60. Wockhardt Recent Developments
- Table 61. Lupin Limited Company Information
- Table 62. Lupin Limited Business Overview
- Table 63. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 64. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 65. Lupin Limited Recent Developments
- Table 66. Fresenius Kabi Company Information
- Table 67. Fresenius Kabi Business Overview
- Table 68. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 69. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 70. Fresenius Kabi Recent Developments
- Table 71. B. Braun Company Information
- Table 72. B. Braun Business Overview
- Table 73. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 74. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 75. B. Braun Recent Developments
- Table 76. USantibiotics Company Information
- Table 77. USantibiotics Business Overview
- Table 78. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 79. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 80. USantibiotics Recent Developments
- Table 81. Qilu Pharmaceutical Company Information
- Table 82. Qilu Pharmaceutical Business Overview
- Table 83. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 84. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Portfolio

- Table 85. Qilu Pharmaceutical Recent Developments
- Table 86. ACS Dobfar Company Information
- Table 87. ACS Dobfar Business Overview
- Table 88. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 89. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 90. ACS Dobfar Recent Developments
- Table 91. Nichi-Iko (Sagent) Company Information
- Table 92. Nichi-Iko (Sagent) Business Overview
- Table 93. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 94. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 95. Nichi-Iko (Sagent) Recent Developments
- Table 96. Antibiotice Company Information
- Table 97. Antibiotice Business Overview
- Table 98. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 99. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Portfolio
- Table 100. Antibiotice Recent Developments
- Table 101. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 102. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2018-2023) & (M Units)
- Table 103. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2018-2023)
- Table 104. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2024-2029) & (M Units)
- Table 105. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Region (2024-2029)
- Table 106. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2018-2023) & (US\$ Million)
- Table 107. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2018-2023)
- Table 108. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2024-2029) & (US\$ Million)
- Table 109. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Region (2024-2029)
- Table 110. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by

Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 111. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2023) & (M Units)

Table 112. North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2024-2029) & (M Units)

Table 113. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 114. North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 115. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 116. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2023) & (M Units)

Table 117. Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2024-2029) & (M Units)

Table 118. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 119. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 120. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 121. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2023) & (M Units)

Table 122. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2024-2029) & (M Units)

Table 123. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 124. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 125. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 126. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2023) & (M Units)

Table 127. Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2024-2029) & (M Units)

Table 128. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 129. Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 130. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 131. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2018-2023) & (M Units)

Table 132. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2024-2029) & (M Units)

Table 133. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2018-2023) & (US\$ Million)

Table 134. Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2024-2029) & (US\$ Million)

Table 135. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2023) & (M Units)

Table 136. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2024-2029) & (M Units)

Table 137. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2018-2023)

Table 138. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2024-2029)

Table 139. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2018-2023) & (US\$ Million)

Table 140. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2024-2029) & (US\$ Million)

Table 141. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2018-2023)

Table 142. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2024-2029)

Table 143. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2018-2023) & (US\$/Unit)

Table 144. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2024-2029) & (US\$/Unit)

Table 145. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2023) & (M Units)

Table 146. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2024-2029) & (M Units)

Table 147. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2018-2023)

Table 148. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2024-2029)

Table 149. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application

(2018-2023) & (US\$ Million)

Table 150. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application

(2024-2029) & (US\$ Million)

Table 151. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2018-2023)

Table 152. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2024-2029)

Table 153. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2018-2023) & (US\$/Unit)

Table 154. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2024-2029) & (US\$/Unit)

Table 155. Key Raw Materials

Table 156. Raw Materials Key Suppliers

Table 157. Beta-lactam and Beta-lactamase Inhibitors Distributors List

Table 158. Beta-lactam and Beta-lactamase Inhibitors Customers List

Table 159. Beta-lactam and Beta-lactamase Inhibitors Industry Trends

Table 160. Beta-lactam and Beta-lactamase Inhibitors Industry Drivers

Table 161. Beta-lactam and Beta-lactamase Inhibitors Industry Restraints

Table 162. Authors List of This Report

List Of Figures

LIST OF FIGURES

Figure 1. Research Methodology

Figure 2. Research Process

Figure 3. Key Executives Interviewed

Figure 4. Beta-lactam and Beta-lactamase Inhibitors Product Picture

Figure 5. Global Beta-lactam and Beta-lactamase Inhibitors Revenue (US\$ Million), 2018 VS 2022 VS 2029

Figure 6. Global Beta-lactam and Beta-lactamase Inhibitors Market Size (2018-2029) & (US\$ Million)

Figure 7. Global Beta-lactam and Beta-lactamase Inhibitors Sales (2018-2029) & (M Units)

Figure 8. Global Beta-lactam and Beta-lactamase Inhibitors Average Price (US\$/Unit) & (2018-2029)

Figure 9. Penicillins Product Picture

Figure 10. Cephalosporins Product Picture

Figure 11. Carbapenems Product Picture

Figure 12. Monobactams Product Picture

Figure 13. Combinations Product Picture

Figure 14. Oral Product Picture

Figure 15. Intravenous Product Picture

Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturers in 2022

Figure 17. Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Manufacturing Sites & Headquarters

Figure 18. Global Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Date of Enter into This Industry

Figure 19. Global Top 5 and 10 Beta-lactam and Beta-lactamase Inhibitors Players Market Share by Revenue in 2022

Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022

Figure 21. Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Figure 22. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region in 2022

Figure 23. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region in 2022

Figure 24. North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country in 2022

Figure 25. North America Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2018-2029)

Figure 26. North America Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2018-2029)

Figure 27. United States Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 28. Canada Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 29. Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country in 2022

Figure 30. Europe Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2018-2029)

Figure 31. Europe Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2018-2029)

Figure 32. Germany Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 33. France Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 34. U.K. Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 35. Italy Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 36. Russia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 37. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Country in 2022

Figure 38. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Country (2018-2029)

Figure 39. Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Country (2018-2029)

Figure 40. China Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 41. Japan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 42. South Korea Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 43. India Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 44. Australia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate

(2018-2029) & (US\$ Million)

Figure 45. China Taiwan Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 46. Indonesia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 47. Thailand Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 48. Malaysia Beta-lactam and Beta-lactamase Inhibitors Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 49. Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country in 2022

I would like to order

Product name: Beta-lactam and Beta-lactamase Inhibitors Industry Research Report 2023

Product link: <https://marketpublishers.com/r/B949DC657C60EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B949DC657C60EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970